SeekingAlpha · Sep 14, 2026
Vericel: MACI And Regenerative Knee Cartilage
Vericel stock outlook: MACI growth, expanded Burlington capacity, BARDA burn-care support, and pipeline catalystsâsee why bulls call VCEL a Buy despite premium.
VC
NASDAQ · VCEL
Vericel Corporation
Healthcare · Biotechnology
$39.72
Up+$1.09 (+2.74%)
Updated Sep 16, 2026, 5:22 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.89B
- P/E ratio
- 144.38
- Dividend yield
- 0.00%
- 52-week range
- $28.95 – $49.32
- Volume
- 654.83K
- Avg. volume
- 728.95K
Price performance
VCEL price history
1M range · 20 trading sessions · Daily adjusted prices
VCEL closed at $39.72 after 20 trading sessions, down 10.26% for the selected period.
- Last close
- $39.72
- Period change
- -10.26%
- Period low
- $37.87
- Period high
- $44.26
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $39.39 | $40.145 | $38.545 | $39.72 | 654.83K |
| Sep 14, 2026 | $38.58 | $39.70 | $38.20 | $39.60 | 629.43K |
| Sep 11, 2026 | $38.39 | $38.945 | $37.35 | $38.34 | 503.53K |
| Sep 10, 2026 | $38.56 | $38.815 | $37.672 | $37.87 | 340.24K |
| Sep 9, 2026 | $38.72 | $39.19 | $38.53 | $38.99 | 366.52K |
| Sep 8, 2026 | $39.69 | $39.72 | $38.74 | $39.08 | 410.3K |
| Sep 4, 2026 | $40.04 | $40.57 | $39.85 | $40.19 | 312.91K |
| Sep 3, 2026 | $41.30 | $41.30 | $40.085 | $40.47 | 301.27K |
| Sep 2, 2026 | $40.49 | $41.49 | $40.35 | $40.89 | 395.53K |
| Sep 1, 2026 | $39.87 | $41.435 | $39.655 | $40.50 | 651.11K |
| Aug 31, 2026 | $40.48 | $40.8808 | $39.34 | $39.90 | 636.31K |
| Aug 28, 2026 | $41.18 | $41.465 | $40.5094 | $40.95 | 491.25K |
| Aug 27, 2026 | $42.39 | $42.65 | $41.16 | $41.18 | 533.52K |
| Aug 26, 2026 | $43.22 | $43.22 | $42.33 | $42.44 | 313.61K |
| Aug 25, 2026 | $42.95 | $43.25 | $42.53 | $43.22 | 465.74K |
| Aug 24, 2026 | $42.68 | $43.34 | $41.95 | $42.30 | 812.27K |
| Aug 21, 2026 | $42.36 | $42.85 | $41.76 | $42.68 | 647.13K |
| Aug 20, 2026 | $42.83 | $43.48 | $41.68 | $42.11 | 567.69K |
| Aug 19, 2026 | $45.04 | $46.01 | $42.89 | $43.57 | 630.19K |
| Aug 18, 2026 | $43.59 | $45.38 | $43.59 | $44.26 | 549.7K |
Latest VCEL news
The latest Smart Investors Daily articles mentioning VCEL.
Stock researchCompany · Overview
VCEL research
Overview
Company profile and research snapshot.
Company profile
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $41.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 28, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel CorporationVericel is
ChartMill · Sep 5, 2026
Vericel (NASDAQ:VCEL) Stands Out on the Affordable Growth Screen
VERICEL CORP (VCEL) fits the Affordable Growth screen with high growth/profitability scores and valuation reasonable relative to biotech peers.
ChartMill · Aug 14, 2026
Vericel (NASDAQ:VCEL): A Strong Growth Play With an Improving Technical Setup
Vericel (VCEL) combines strong growth & profitability with a promising technical setup, making it a standout Strong Growth breakout pick.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
